Stock ACXP ACURX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq
Other stock markets
 21:00:00 27/06/2024 BST 		5-day change 1st Jan Change
2.31 USD +3.12% Intraday chart for Acurx Pharmaceuticals, Inc. +3.59% -39.69%
05-15 Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection CI
05-15 Transcript : Acurx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 15, 2024

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
PR
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
PR
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
PR
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
PR
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
PR
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV
NE
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
PR
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
PR
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
AQ
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
PR
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
PR
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024, February 1, 2024
AQ
Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
PR
Acurx Pharmaceuticals' Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)
AQ
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
PR
Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
PR
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
PR
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
PR
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACXP Stock
  4. News Acurx Pharmaceuticals, Inc.
  5. Press Releases